An update on iron chelation therapy

Affiliations

Review

Erika Poggiali et al. Blood Transfus. 2012 Oct.

. 2012 Oct;10(4):411-22.

doi: 10.2450/2012.0008-12. Epub 2012 Jun 27.

¹ IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, Department of Internal Medicine, University of Milan, Italy.

No abstract available

Comment in

Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome.
Molica M, Salaroli A, Alimena G, Breccia M. Molica M, et al. Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s162-3. doi: 10.2450/2013.0005-13. Epub 2013 Apr 15. Blood Transfus. 2014. PMID: 23736908 Free PMC article. No abstract available.

1. Shander A, Cappellini MD, Goodnough L. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang. 2009;97:185–97. - PubMed
1. Kushner JP, Porter JB, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001. pp. 47–61. http://asheducationbook.hematologylibrary.org/archive/index.dtl. - PubMed
1. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78:487–94. - PubMed
1. Hershko C, Abrahamov A, Konijm AM, et al. Objectives and methods of iron chelation therapy. Bioinorg Chem Apl. 2003;1:151–68. - PMC - PubMed
1. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327–31. - PubMed